OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors
Joana Lima Ferreira, Cláudia Costa, Bernardo Marques, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 2, pp. 299-309
Closed Access | Times Cited: 44
Joana Lima Ferreira, Cláudia Costa, Bernardo Marques, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 2, pp. 299-309
Closed Access | Times Cited: 44
Showing 26-50 of 44 citing articles:
Clinical biomarkers for thyroid immune-related adverse events in patients with stage III and IV gastrointestinal tumors
Na Xing, Jing Liu, Lin Hou, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Na Xing, Jing Liu, Lin Hou, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Reversible elevation of creatine kinase and creatinine caused by sintilimab-induced hypothyroidism: A case report
Shurong Liu, Zhonglin Zhao, Rui-Ren Zhai, et al.
Medicine (2024) Vol. 103, Iss. 42, pp. e40080-e40080
Open Access | Times Cited: 1
Shurong Liu, Zhonglin Zhao, Rui-Ren Zhai, et al.
Medicine (2024) Vol. 103, Iss. 42, pp. e40080-e40080
Open Access | Times Cited: 1
Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma
Lei Xu, Chao Leng, Lin Chen, et al.
International Journal of Cancer (2021) Vol. 150, Iss. 3, pp. 472-481
Open Access | Times Cited: 10
Lei Xu, Chao Leng, Lin Chen, et al.
International Journal of Cancer (2021) Vol. 150, Iss. 3, pp. 472-481
Open Access | Times Cited: 10
Does Clinical and Biochemical Thyroid Dysfunction Impact on Endometrial Cancer Survival Outcomes? A Prospective Database Study
Chloe E. Barr, Kelechi Njoku, Leo Hotchkies, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5444-5444
Open Access | Times Cited: 8
Chloe E. Barr, Kelechi Njoku, Leo Hotchkies, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5444-5444
Open Access | Times Cited: 8
Cutaneous, oral and genital lichenoid reactions associated with retifanlimab, a new PD ‐1 inhibitor
Claire van Damme, Anne Demols, V. del Mármol
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 3
Closed Access | Times Cited: 5
Claire van Damme, Anne Demols, V. del Mármol
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 3
Closed Access | Times Cited: 5
Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
Yiran Lu, Qingchen Li, Lusi Xu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 18, pp. 16501-16510
Open Access | Times Cited: 2
Yiran Lu, Qingchen Li, Lusi Xu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 18, pp. 16501-16510
Open Access | Times Cited: 2
Thyroid Dysfunction from Treatments for Solid Organ Cancers
Anupam Kotwal, Donald S.A. McLeod
Endocrinology and Metabolism Clinics of North America (2022) Vol. 51, Iss. 2, pp. 265-286
Closed Access | Times Cited: 4
Anupam Kotwal, Donald S.A. McLeod
Endocrinology and Metabolism Clinics of North America (2022) Vol. 51, Iss. 2, pp. 265-286
Closed Access | Times Cited: 4
CASE OF INDUCED GRAVE’S DISEASE BY NIVOLUMAB TREATMENT
Ketevan Lomidze, MARINA GORDELADZE, Nino Kikodze, et al.
EXPERIMENTAL & CLINICAL MEDICINE GEORGIA (2024)
Open Access
Ketevan Lomidze, MARINA GORDELADZE, Nino Kikodze, et al.
EXPERIMENTAL & CLINICAL MEDICINE GEORGIA (2024)
Open Access
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival
Mario Giovanni Chilelli, Carlo Signorelli, Julio Rodrigo Giròn Berrìos, et al.
Cancer Diagnosis & Prognosis (2022) Vol. 2, Iss. 1, pp. 55-63
Open Access | Times Cited: 2
Mario Giovanni Chilelli, Carlo Signorelli, Julio Rodrigo Giròn Berrìos, et al.
Cancer Diagnosis & Prognosis (2022) Vol. 2, Iss. 1, pp. 55-63
Open Access | Times Cited: 2
Outcomes and Management of Immune Checkpoint Inhibitor–Induced Hypothyroidism: A Retrospective Analysis
Allison L. Phillips, David J. Reeves
Annals of Pharmacotherapy (2022) Vol. 56, Iss. 10, pp. 1100-1105
Closed Access | Times Cited: 2
Allison L. Phillips, David J. Reeves
Annals of Pharmacotherapy (2022) Vol. 56, Iss. 10, pp. 1100-1105
Closed Access | Times Cited: 2
Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysis
Yuhao Wei, Yun Hong, Xueyan Zhou, et al.
Research Square (Research Square) (2023)
Open Access
Yuhao Wei, Yun Hong, Xueyan Zhou, et al.
Research Square (Research Square) (2023)
Open Access
Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
Yiran Lu, Qingchen Li, Lusi Xu, et al.
Research Square (Research Square) (2023)
Open Access
Yiran Lu, Qingchen Li, Lusi Xu, et al.
Research Square (Research Square) (2023)
Open Access
[Correlation Analysis between Thyroid Function Abnormality and Efficacy in Patients
with Advanced Non-small Cell Lung Cancer after Immunotherapy].
Yibo Wang, Xinjuan Wang, Lin Cheng, et al.
PubMed (2023) Vol. 26, Iss. 5, pp. 369-376
Closed Access
Yibo Wang, Xinjuan Wang, Lin Cheng, et al.
PubMed (2023) Vol. 26, Iss. 5, pp. 369-376
Closed Access
RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Rena Pollack, Joshua Stokar, Natan Lishinsky, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10526-10526
Open Access
Rena Pollack, Joshua Stokar, Natan Lishinsky, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10526-10526
Open Access
Inibitori dei checkpoint immunitari e patologia tiroidea
Luca Patti, Laura Musso, Diego Ferone, et al.
L Endocrinologo (2022) Vol. 23, Iss. 2, pp. 125-132
Open Access
Luca Patti, Laura Musso, Diego Ferone, et al.
L Endocrinologo (2022) Vol. 23, Iss. 2, pp. 125-132
Open Access
Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study
Lingge Wu, Yan Xu, Xiang Wang, et al.
Research Square (Research Square) (2022)
Open Access
Lingge Wu, Yan Xu, Xiang Wang, et al.
Research Square (Research Square) (2022)
Open Access
Case 5: A 41-Year-Old Woman With Palpitation
Ji Won Yang, Kabsoo Shin, Jeongmin Lee, et al.
Journal of Korean Medical Science (2022) Vol. 37, Iss. 47
Open Access
Ji Won Yang, Kabsoo Shin, Jeongmin Lee, et al.
Journal of Korean Medical Science (2022) Vol. 37, Iss. 47
Open Access
Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
Han-Sang Baek, Chaiho Jeong, Kabsoo Shin, et al.
Research Square (Research Square) (2021)
Open Access
Han-Sang Baek, Chaiho Jeong, Kabsoo Shin, et al.
Research Square (Research Square) (2021)
Open Access
Ipilimumab/nivolumab/pembrolizumab
Reactions Weekly (2021) Vol. 1859, Iss. 1, pp. 201-201
Closed Access
Reactions Weekly (2021) Vol. 1859, Iss. 1, pp. 201-201
Closed Access
